Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 2,210,000 shares, a growth of 10.5% from the November 30th total of 2,000,000 shares. Based on an average daily volume of 543,300 shares, the short-interest ratio is currently 4.1 days.
Axon Enterprise Stock Up 0.2 %
NASDAQ AXON traded up $0.35 during midday trading on Monday, hitting $165.93. 11,310 shares of the company traded hands, compared to its average volume of 454,035. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.79 and a quick ratio of 2.39. The company has a market cap of $11.81 billion, a PE ratio of 114.43 and a beta of 0.79. The company’s 50-day simple moving average is $169.56 and its 200-day simple moving average is $137.86. Axon Enterprise has a 52 week low of $82.49 and a 52 week high of $193.85.
Insiders Place Their Bets
In related news, COO Joshua Isner sold 275 shares of the company’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $177.96, for a total value of $48,939.00. Following the transaction, the chief operating officer now owns 237,576 shares in the company, valued at $42,279,024.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Joshua Isner sold 275 shares of the company’s stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $177.96, for a total value of $48,939.00. Following the transaction, the chief operating officer now owns 237,576 shares of the company’s stock, valued at $42,279,024.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Luke Larson sold 4,523 shares of the company’s stock in a transaction on Monday, December 5th. The stock was sold at an average price of $186.40, for a total transaction of $843,087.20. Following the completion of the transaction, the president now directly owns 276,628 shares in the company, valued at approximately $51,563,459.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,261 shares of company stock valued at $4,036,474. Corporate insiders own 6.90% of the company’s stock.
Institutional Trading of Axon Enterprise
Several hedge funds and other institutional investors have recently bought and sold shares of AXON. JPMorgan Chase & Co. boosted its position in Axon Enterprise by 0.4% during the 1st quarter. JPMorgan Chase & Co. now owns 132,122 shares of the biotechnology company’s stock valued at $18,197,000 after acquiring an additional 541 shares in the last quarter. American Century Companies Inc. boosted its position in Axon Enterprise by 103.8% during the 1st quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock valued at $853,000 after acquiring an additional 3,155 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Axon Enterprise by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 12,493 shares of the biotechnology company’s stock valued at $1,721,000 after acquiring an additional 486 shares in the last quarter. Cetera Advisors LLC boosted its position in Axon Enterprise by 12.9% during the 1st quarter. Cetera Advisors LLC now owns 3,333 shares of the biotechnology company’s stock valued at $459,000 after acquiring an additional 382 shares in the last quarter. Finally, Private Advisor Group LLC boosted its position in Axon Enterprise by 40.3% during the 1st quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 994 shares in the last quarter. Institutional investors own 75.62% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. Morgan Stanley raised their target price on shares of Axon Enterprise from $130.00 to $155.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 13th. Credit Suisse Group boosted their target price on shares of Axon Enterprise from $142.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, November 9th. Needham & Company LLC upped their price target on shares of Axon Enterprise from $130.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, November 9th. Barclays assumed coverage on shares of Axon Enterprise in a report on Thursday, September 15th. They set an “overweight” rating and a $147.00 price target on the stock. Finally, Northland Securities upped their price target on shares of Axon Enterprise from $140.00 to $160.00 in a report on Wednesday, November 9th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $175.13.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axon Enterprise wasn’t on the list.
While Axon Enterprise currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
